Molbio Diagnostics’ stock rises after Jefferies initiates coverage with a Buy rating and calls it a “high conviction top pick” among medical technology stocks. Shares move sharply upward on the NSE, reaching a day high of Rs 1,369.20 before paring gains and trading about 4% higher at Rs 1,305 per share.
Economic Times reports that Jefferies sets a target price of Rs 1,600, which it frames as implying potential upside from the prior close. The outlet also places the move in the context of the stock’s recent trading history, including its listing at a premium and its comparison to the IPO price. NDTV similarly focuses on the intraday price action and the extent of gains, without adding new details on the brokerage’s target or valuation assumptions.
